Resectable Localized Prostate Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Resectable Localized Prostate Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingEarly Phase 1

NCT06408298

HCQ in Resectable Localized Prostate Cancer

This is randomized, double blind, placebo controlled proof of principle (window of opportunity) study of oral hydroxychloroquine in patients with resectable loc…

United States20 participantsStarted 2026-01-06

Treatment: Hydroxychloroquine Sulfate 400Mg Tab, Placebo

All recent trials (3 shown)

CompletedPhase 1

NCT03177460

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Lo…

This phase I trial studies the side effects of daratumumab or FMS inhibitor JNJ-40346527 before surgery in treating patients with high-risk prostate cancer that…

United States33 participantsStarted 2017-06-07

Treatment: Daratumumab, FMS Inhibitor JNJ-40346527

CompletedPhase 3

NCT00538850

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for br…

United States130 participantsStarted 2007-10

Treatment: Fentanyl sublingual spray, Placebo